MSB 3.21% $1.13 mesoblast limited

Ann: Update on BLA for Graft Versus Host Disease, page-678

  1. 869 Posts.
    lightbulb Created with Sketch. 196
    personally I’d put more weight on what the FDA has said and what other (successful) companies do

    MSB/ SI’s track record isn’t great and his comments yesterday about how Aussie investors don’t understand biotech are telling

    each to their own I guess

    imho
    not investment advice
    DYOR
    etc

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.